Orexo develops improved pharmaceuticals and digital therapies addressing unmet needs mainly within the growing space of addiction. The products are commercialized by Orexo in the US or via partners worldwide. The main market today is the American market for buprenorphine/naloxone products, where Orexo commercializes its lead product Zubsolv® for treatment of opioid use disorder. Total net sales for 2019 amounted to SEK 845 million and the number of employees was 128.
Developed 4 products approved worldwide
Orexo has developed four products from concept to patient. The products have been approved in multiple markets and helped patients benefit from improved drugs worldwide.
Pipeline focusing on addiction in all phases
Filling an unmet need among healthcare professionals and patients is the key in the work of developing new innovative treatments. The pipeline contains development projects with a primary therapeutic focus around addiction in all phases, from prevention to treatment.
Key market characterized by strong growth
The opioid problem in the US is on an epidemic level. In 2019 the use of synthetic opioids such as fentanyl caused an increasing number of deaths, while the overall number of overdose deaths declined slightly. There is still a huge need for treatment and in 2019 the dynamic buprenorphine/naloxone market, where Orexo commercializes its lead product, grew 14 percent.1
Profitable company with strong cash position
Since 2016 Orexo is a profitable company and for the full year of 2019 EBITDA amounted to SEK 272 million and the cash position to SEK 817 million.
Strategic focus on product expansion
One of Orexo’s objectives for long-term growth is to broaden the US commercial platform, by M&A transactions, to leverage scale and expand sales.
1 IQVIA Data